BC Extra | Apr 23, 2019
Company News

Pilot program for GSK's malaria vaccine starts in Malawi

WHO launched a planned pilot program of GSK's malaria vaccine RTS,S in Malawi on Tuesday with the goal of informing the organization's policy recommendations for broader use of the vaccine. The organization will also roll...
BC Week In Review | Oct 27, 2017
Clinical News

GSK begins Phase II of malaria vaccine candidate

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) began a Phase II trial of intramuscular RTS,S vaccine (Mosquirix, GSK257049) to vaccinate against malaria infection. The open-label, U.S. trial will evaluate adult and pediatric formulations of the vaccine in 160...
BC Innovations | Apr 6, 2017
Distillery Techniques


TECHNOLOGY: Plasma markers Blood levels of immune cell markers and antibodies could help predict protective responses to Plasmodium CSP -based malaria vaccines. A cohort of 46 healthy volunteers received one of two malaria vaccine regimens...
BC Week In Review | Jan 12, 2017
Company News

GeneCentric, Bristol-Myers Squibb deal

Bristol-Myers Squibb and GeneCentric partnered to explore the feasibility of using GeneCentric’s Cancer Subtype Platform (CSP) to identify translational biomarkers for cancer drug Opdivo nivolumab for use in clinical trials. The pharma will provide undisclosed...
BC Week In Review | Jan 6, 2017
Clinical News

GAP3KO vaccine: Ph I data

An open-label, U.S. Phase I trial in 10 healthy volunteers showed that GAP3KO administered via the bite of 150-200 GAP3KO-infected mosquitoes under controlled conditions prevented malaria infection in all subjects. Specifically, all 10 subjects developed...
BC Week In Review | Oct 19, 2015
Company News

Oberland Capital Management LLC, Agenus deal

Agenus sold its royalty stream on sales of shingles vaccine HZ/su and malaria vaccine RTS,S ( Mosquirix ) to Oberland for a $100 million note. Agenus will receive an additional $15 million note if FDA approves HZ/su,...
BC Week In Review | Jul 27, 2015
Clinical News

RTS regulatory update

EMA’s CHMP recommended approval of Mosquirix from GlaxoSmithKline for active immunization of children ages 6 weeks to 17 months against malaria caused by Plasmodium falciparum and against hepatitis B. The malaria vaccine targeting the circumsporozoite...
BC Extra | Jul 25, 2015
Company News

CHMP backs GSK's malaria vaccine

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) received a positive opinion from EMA's CHMP for its Mosquirix malaria vaccine in children aged 6 weeks to 17 months -- moving the product a step closer to becoming the first...
BC Innovations | Jan 15, 2015
Distillery Therapeutics

Therapeutics: Plasmodium sporozoite asparagine-rich protein (SLARP); P. falciparum circumsporozoite protein B9 (B9; CSP)

Infectious disease INDICATION: Malaria In vitro and mouse studies suggest a genetically attenuated parasite could be used to vaccinate against malaria. Plasmodium berghei with engineered deletions of the B9 and SLARP genes - which are required...
BC Week In Review | Jul 28, 2014
Clinical News

RTS regulatory update

EMA accepted for review an MAA from GlaxoSmithKline for its RTS,S malaria vaccine - moving the product closer to being the first vaccine approved to prevent malaria infection in infants and children. There are currently no...
Items per page:
1 - 10 of 37